Stephanie Allan, MS, CCRC

The University of Utah: Biology, B.S.

The Ohio State University: Clinical Pharmacology, M.S.

Stephanie Allan currently serves a Clinical Scientist at Proxima Clinical Research, Inc. Proxima is a contract research organization focused on assisting emerging pharmaceutical and medical device companies in clinical product development. In her role, Stephanie helps write and design clinical trials in line with the current phase of product development and regulatory strategy.

Previously, she has helped write and design investigator-sponsored trials at Huntsman Cancer Institute in Salt Lake City, Utah. There she gained extensive oncology experience in solid tumors and hematological malignancies and dyscrasias. Her prior clinical research experience includes trial management, clinical development, and medical writing.

Stephanie earned a Bachelor of Science in Biology with a minor in Chemistry from the University of Utah. She went on to receive her Master of Science in Clinical Pharmacology with an emphasis in Clinical Trial Design from The Ohio State University. She is a Certified Clinical Research Coordinator through the Association of Clinical Research Professionals. Over the course of her carrier, she has developed a working knowledge of FDA regulations, OHRP, ICH, ethical guidelines, clinical trial conduct, and study design.

‍

Proxima Clinical Research, Inc., Houston, Texas
Clinical Scientist

Huntsman Cancer Institute, Salt Lake City, Utah
Investigator-Initiated Trial Developer

Huntsman Cancer Institute, Salt Lake City, Utah
Senior Oncology Clinical Research Coordinator

Salt Lake Community College, Salt Lake City, Utah
Biology Adjunct Instructor

Ms. Allan has played an important role in the development of the following medical products:

1. A Phase I study evaluating the safety and efficacy of selinexor in combination with ibrutinib in subjects with Chronic Lymphocytic Lymphoma (CLL).
2. Randomized, double-blind, placebo-controlled study of celecoxib to help manage post-surgical opioid use and functional outcomes for subjects with advanced-stage head and neck cancer.
3. A Phase I dose-escalation trial of intraperitoneal oxaliplatin in combination with mFOLFIRI in subjects with peritoneal carcinomatosis from colorectal and appendiceal cancer.
4. A Phase Ib study of osimertinib in combination with ipilimumab in subjects with EGFR mutated non-small cell lung cancer.
5. A Phase II study of staggered chemo-immunotherapy with durvalumab, pemetrexed, and carboplatin in subjects with metastatic non-squamous NSCLC.
6. A Phase IB/II study of nivolumab in combination with radium-223 in men with metastatic castration-resistant prostate cancer.
7. A phase I trial of ulixertinib (BVD-523) and hydroxychloroquine in subjects with advanced MAPK-mutated gastrointestinal adenocarcinomas.
8. A phase 2 basket trial of ulixertinib in combination with hydroxychloroquine in advanced gastrointestinal malignancies harboring MAPK pathway mutations.
9. A phase 2 trial of cobimetinib in newly diagnosed or HMA-treated CMML patients with RAS pathway mutations
10. A Phase II study of itacitinib and extracorporeal photopheresis (ECP) for the first-line treatment of chronic graft versus host disease.
11. A feasibility trial of a new functional precision oncology program for metastatic breast cancer incorporating full genome testing and drug sensitivity testing on patient-derived organoids.
12. A phase I study to evaluate the safety and efficacy of belinostat in combination with nivolumab alone and with Ipilimumab in patients with previously treated metastatic or advanced carcinomas enriched for ARID1A loss of function (lof) mutation.
13. A Phase II randomized controlled trial of a supplement containing quercetin, bromelain, and papain on reducing the severity of radiation-induced prostatitis.
14. A study evaluating the safety and efficacy of a new stent intended for pediatric use.  
15. A Phase I, first-in-human, study of a new drug intended for neuroprotection post-stroke.